(Q44770291)

6 December 2017

title

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

6 December 2017

González-Porras JR

1 reference

6 December 2017

Hernández JM

1 reference

6 December 2017

Polo-Zarzuela M

1 reference

6 December 2017

Sureda A

1 reference

6 December 2017

Barrenetxea C

1 reference

6 December 2017

Palomera L

1 reference

6 December 2017

López R

1 reference

6 December 2017

Grande-García C

1 reference

6 December 2017

Alegre A

1 reference

6 December 2017

Vargas-Pabón M

1 reference

6 December 2017

Gutiérrez ON

1 reference

6 December 2017

Rodríguez JA

1 reference

6 December 2017

San Miguel JF

1 reference

6 December 2017

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

856-863

1 reference

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

The role of chemotherapy in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thromboembolic events during treatment with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

Thalidomide in refractory and relapsing multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Use a gentle approach for refractory myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Gentle yet effective treatment for elderly patients with refractory or relapsing multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Combination of interferon and dexamethasone in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403322

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403322

1 reference

Dimensions Publication ID

6 December 2017

1013052689

0 references

1 reference